By SPC News Staff
The FDA has granted a new indication for Thymoglobulin (anti-thymocyte globulin [rabbit]), from Sanofi Genzyme, for use with concomitant immunosuppression for the prophylaxis of acute rejection in patients receiving a kidney transplant.
“Thymoglobulin has been a well-established medication used in kidney transplantation for nearly 20 years, and this FDA approval is an important milestone for the transplant community,” said Daniel Brennan, MD, a professor of medicine